1. Home
  2. CPAY vs ICUCW Comparison

CPAY vs ICUCW Comparison

Compare CPAY & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corpay Inc.

CPAY

Corpay Inc.

HOLD

Current Price

$309.97

Market Cap

21.7B

Sector

Technology

ML Signal

HOLD

Logo SeaStar Medical Holding Corporation Warrant

ICUCW

SeaStar Medical Holding Corporation Warrant

HOLD

Current Price

$0.01

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPAY
ICUCW
Founded
1986
N/A
Country
United States
United States
Employees
N/A
18
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.7B
N/A
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
CPAY
ICUCW
Price
$309.97
$0.01
Analyst Decision
Buy
Analyst Count
11
0
Target Price
$369.64
N/A
AVG Volume (30 Days)
527.9K
N/A
Earning Date
02-04-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
5.04
N/A
EPS
14.72
N/A
Revenue
$4,314,608,000.00
N/A
Revenue This Year
$15.86
N/A
Revenue Next Year
$15.55
N/A
P/E Ratio
$21.07
N/A
Revenue Growth
11.27
N/A
52 Week Low
$252.84
N/A
52 Week High
$400.81
N/A

Technical Indicators

Market Signals
Indicator
CPAY
ICUCW
Relative Strength Index (RSI) 57.54 39.98
Support Level $301.00 $0.01
Resistance Level $316.01 $0.01
Average True Range (ATR) 7.54 0.00
MACD -0.60 0.00
Stochastic Oscillator 50.92 49.09

Price Performance

Historical Comparison
CPAY
ICUCW

About CPAY Corpay Inc.

Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. Its suite of modern payment solutions helps customers manage vehicle-related expenses, lodging expenses, and corporate payments. Its reportable segments are; Vehicle Payments, Corporate Payments, Lodging Payments, and Other. The group's geographic areas are the United States, Brazil, the United Kingdom, and Other.

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: